EIF2AK3 and familial pancreatic carcinoma: It is imperative to consider and investigate the potential unintended effects of these (often nonspecific) inhibitors to ensure that any possible off-target effects are rigorously explored to prevent toxicity, similar to what has been observed with PERK inhibition in pancreatic cancer (198).